Switching to Subcutaneous Zilucoplan from Intravenous Complement Component 5 Inhibitors in Myasthenia Gravis: Patient Preference and Satisfaction from a Phase 3b Study (P1-11.009)
To evaluate safety, efficacy, patient preference and satisfaction with zilucoplan in adults with acetylcholine receptor autoantibody–positive generalized myasthenia gravis (MG) switching from their current intravenous complement component 5 (C5) inhibitors to subcutaneous zilucoplan.
Authors
- Jos Bloemers (ORCID: https://orcid.org/0000-0001-5637-7606)
- Shaida Khan (ORCID: https://orcid.org/0000-0002-8799-003X)
- Puneet Kumar Singh (ORCID: https://orcid.org/0000-0002-4640-8365)
- Miriam Freimer (ORCID: https://orcid.org/0000-0001-8282-764X)
- Min Kyun Kang (ORCID: https://orcid.org/0000-0002-3843-1645)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Samir Macwan
- Urvi Desai (ORCID: https://orcid.org/0000-0002-5169-3201)
- Michael D. Weiss (ORCID: https://orcid.org/0000-0003-4064-1032)
- Bhupendra Khatri (ORCID: https://orcid.org/0000-0002-1843-5585)
- Perry B. Shieh (ORCID: https://orcid.org/0000-0001-7145-7663)
- Babak Boroojerdi
- Raghav Govindarajan (ORCID: https://orcid.org/0000-0003-0419-9072)
- Andreea Lavrov
- Todd Levine
- Eumorphia Maria Delicha
Institutions
- University of North Carolina at Chapel Hill (US)
- Eisenhower Medical Center (US)
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- St. Elizabeth Hospital in Enumclaw (US)
- University of Washington Medical Center (US)
- St. Elizabeths Hospital (US)
- The Ohio State University Wexner Medical Center (US)
- St. Elizabeth's Medical Center (US)
- Southwestern Medical Center (US)
- HonorHealth (US)
- UCB Pharma (Germany) (DE)
- Southwestern Medical Center (US)
- Wake Forest University (US)
- UCB Pharma (Belgium) (BE)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208791
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00